Journal of Clinical Oncology
Articles in this Issue
Integration of genomic classification and clinical characteristics as a predictor of survival in de novo metastatic prostate cancer.
123 Background: Genomic assessment has revolutionized cancer care and individual gene alterations inform prognosis and pre...
Assessing the impact of cardiovascular disease and ADT on survival disparities in prostate cancer.
268 Background: US Black men are on average diagnosed with more aggressive prostate cancer (PCa) and have higher mortality...
Effect of upfront dose reductions on efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.
696 Background: EVP is the preferred 1st-line therapy for patients (pts) with aUC. Upfront EV dose reductions may be utili...
TulmiSTAR-02: A phase I/II open-label study of dose escalation and expansion of tulmimetostat in combination with darolutamide versus darolutamide, and tulmimetostat with abiraterone in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
TPS302 Background: Patients (pts) with mHSPC, especially those with high-volume disease, have a poor prognosis due to prog...
The EMPOWER trial: Evaluating a home-based physical activity program (PAP) with the ExerciseRx digital platform vs. health education (HE) in people with non-muscle invasive bladder cancer (NMIBC).
TPS881 Background: The NMIBC population is emblematic of older patients with cancer, with a high burden of frailty, sarcop...
SPECTRA study: A phase II trial of supraphysiological androgen to enhance treatment activity with DNA-damaging agents in men with metastatic castration resistant prostate cancer (mCPRC).
TPS279 Background: Prostate cancer models exhibit paradoxical growth suppression following exposure to supraphysiological...
Long-term clinical outcomes with <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).
507 Background: Two randomized phase I trials demonstrated that CBM588, a live biotherapeutic, may enhance the antitumor e...
Impact of social environment on prostate cancer care across the clinical risk spectrum for Black men treated in community settings.
329 Background: Social environment impacts prostate cancer (PCa) care, particularly for Black men, but whether its effect...
Evaluation of ancillary multiparametric MRI features in PI-RADS 3 prostate lesions and their association with prostate cancer.
26 Background: Prostate cancer (PCa) remains the leading malignancy among men in Colombia and a major cause of cancer-rela...
Clinical outcomes with immune checkpoint inhibitor and/or enfortumab vedotin in patients with MTAP-deleted metastatic urothelial carcinoma.
757 Background: MTAP-deletion(d) in urothelial carcinoma (UC) is associated with tumor aggressiveness, higher rates of met...
Phase 2 trial of belzutifan in participants from China and Japan with von Hippel-Lindau disease-associated tumors: Results from LITESPARK-015 cohort B1.
494 Background: Von Hippel-Lindau (VHL) disease manifests with tumors including renal cell carcinoma (RCC), central nervou...
A national analysis of the impact of opioid use disorder on clinical outcomes in hospitalized patients with urothelial carcinoma.
659 Background: Patients with urothelial carcinoma often require hospitalizations for peri and post operative management o...
A novel cabozantinib formulation with reduced pharmacokinetic variability and the potential to improve safety in patients with renal cell carcinoma.
512 Background: Cabozantinib is a standard treatment for advanced renal cell carcinoma (RCC) which exhibits substantial ph...
Impact of piflufolastat F18 imaging on disease management for prostate cancer patients: Observations from the PYLARIFY Registry study.
339 Background: PSMA-PET imaging is widely accepted as preferred to conventional imaging (CT, MRI, SPECT) for the manageme...
Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906.
586 Background: Active surveillance (AS) remains a preferred option for clinical stage 1 (CS1) TGCT. Biomarkers to predict...
OncoEducate: A pilot study of generative AI to support patient education in GU cancer care.
713 Background: Genitourinary (GU) cancer care involves complex treatment plans and goals, which can be difficult for pati...
Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.
516 Background: Circulating tumor DNA (ctDNA) has emerged as a powerful tool for detecting molecular residual disease (MRD...
Acute kidney injury to predict cardiovascular outcomes following radical cystectomy: A multicenter retrospective study.
725 Background: Acute kidney injury (AKI) is a common complication in patients undergoing radical cystectomy (RC). Althoug...
Circulating tumor DNA (ctDNA) as a real-time biomarker in marker-negative germ cell tumors (GCT): A proof-of-concept study.
619 Background: Traditional GCT biomarkers include AFP, β-HCG, and LDH. Marker-negative GCTs—comprising seminoma, embryona...
Feasibility and outcomes of response-adapted and retreatment <sup>177</sup> Lu-PSMA-617 therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
184 Background: The depth and time to response vary among patients with mCRPC receiving Lutetium-177 prostate-specific mem...
Association between metabolic syndrome and treatment outcomes in metastatic prostate cancer: A retrospective cohort analysis.
95 Background: Metabolic syndrome (MetS) affects 25–27% of metastatic prostate cancer patients (mPCa) receiving androgen d...
Comprehensive plasma metabolomic profiling of metastatic urothelial carcinoma (mUC) pre- and post-immune checkpoint inhibitor (ICI) or platinum-based chemotherapy (PBC).
795 Background: Comprehensive plasma metabolomic profiling of mUC patients may identify mechanisms of resistance and new t...
Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02).
TPS412 Background: PARP inhibitors (PARPi) are approved for the treatment of patients with metastatic castration-resistant...
Short term intensified pembrolizumab and tivozanib for high-risk renal cell carcinoma: STRIKE! (Alliance A032201).
TPS577 Background: Pembrolizumab (pembro) for one year following resection of localized high risk clear cell renal cell ca...
Phase 1/2 OMAHA-U01 substudy 01A: Oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
TPS585 Background: mCRPC remains an incurable disease and therapeutic agents with novel mechanisms of action are needed fo...